IMI-2 carbapenemase in a clinical Klebsiella variicola isolated in the UK

J Antimicrob Chemother. 2017 Jul 1;72(7):2129-2131. doi: 10.1093/jac/dkx103.

Authors

Affiliations

¹ Antimicrobial Resistance and Healthcare Associated Infections (AMRHAI) Reference Unit, National Infection Service, Public Health England, London NW9 5EQ, UK.
² Specialist Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology Cardiff, University Hospital of Wales, Heath Park, Cardiff CF14 4XW, UK.
³ Ysbyty Gwynedd, Bangor LL57 2PW, UK.

PMID: 28379381
DOI: 10.1093/jac/dkx103

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Anti-Bacterial Agents / pharmacology*
Bacterial Proteins / genetics*
Carbapenem-Resistant Enterobacteriaceae / drug effects
Carbapenem-Resistant Enterobacteriaceae / enzymology*
Carbapenem-Resistant Enterobacteriaceae / genetics
Carbapenem-Resistant Enterobacteriaceae / isolation & purification
Carbapenems / pharmacology*
Cephalosporins / pharmacology
Drug Resistance, Bacterial
Ertapenem
Gene Transfer, Horizontal
Humans
Imipenem / pharmacology
Klebsiella / drug effects
Klebsiella / enzymology*
Klebsiella / genetics
Klebsiella / isolation & purification
Meropenem
Plasmids
Thienamycins / pharmacology
United Kingdom
beta-Lactamases / genetics*
beta-Lactams / pharmacology

Substances

Anti-Bacterial Agents
Bacterial Proteins
Carbapenems
Cephalosporins
Thienamycins
beta-Lactams
Imipenem
beta-Lactamases
carbapenemase
Meropenem
Ertapenem